Management challenges in low-grade serous ovarian cancer with a BRCA mutation

Int J Gynecol Cancer. 2024 Apr 1;34(4):631-636. doi: 10.1136/ijgc-2023-005240.

Authors

Luisa Sanchez-Lorenzo¹, Lidia Sancho², Teresa Iscar³, Rachel Grisham⁴, Luis Chiva⁵

Affiliations

¹ Deparment of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain lsanchezl@unav.es.
² Nuclear Medicine, Clinica Universidad de Navarra, Madrid, Spain.
³ Pathology, Clínica Universidad de Navarra, Madrid, Spain.
⁴ Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁵ Department of Gynecology and Obstetrics, Clinica Universidad de Navarra, Madrid, Spain.

PMID: 38561200
DOI: 10.1136/ijgc-2023-005240

No abstract available

Keywords: BRCA1 Protein; BRCA2 Protein; Ovarian Cancer.

MeSH terms

BRCA1 Protein / genetics
BRCA2 Protein / genetics
Cystadenocarcinoma, Serous* / genetics
Female
Germ-Line Mutation
Humans
Mutation
Ovarian Neoplasms* / genetics

Substances

BRCA1 Protein
BRCA2 Protein